Clinical Trial Search

Primary: Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy — 2.44; 2.42; 1.77…

Primary: Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7 — 96.97; 99.05; 99.05; 99.05 percentage of participants

Primary: Number of Participants Who Are Pain Free at 2 Hours Post-Dose — 61; 27 Participants

Primary: The Percentage of Seroresponders to the Modified Process Hepatitis B Vaccine (5 μg and 10 μg Dose), RECOMBIVAX HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and…

Primary: Mean Change in the Symptom Identified by the Patient to be Most Bothersome — -1.71; -1.77; -1.11; -1.10 Scores on a scale

Primary: Incidence of Arthropathy (Cumulative) — 39; 9; 64; 16 participants

Primary: Change in Systolic Blood Pressure — -16.6; -15.9; -21.8; -18.9 mm Hg

Primary: Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C — -27.4; -11.0 Percent Change — p=<0.001

Primary: Total Walking Distance — 618; 572 meter — p=<0.05

Primary: Clinical Remission — 17.8; 19.2 percentage of participants — p=.858

Primary: Young Mania Rating Scale (YMRS) Total Score Change From Baseline — -3.8; -4.0; -6.3; -6.1 score on scale

Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at Week 52 — -3.6; -5.5 score on a scale — p=0.003

Primary: The Number of Seroresponders to the Modified Process Hepatitis B Vaccine and RECOMBIVAX HB™ (Currently Licensed Vaccine) — 115; 100 Participants

Primary: Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12 — -0.4; 0.4 Percent — p=<0.001

Primary: Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody. — 233; 111 Subjects